AstraZeneca’s Alexion enters into drug discovery collaboration with Verge Genomics
Alexion will obtain access to the US-based biotechnology company’s CONVERGE platform to identify novel disease targets, in exchange…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Sep 23
Alexion will obtain access to the US-based biotechnology company’s CONVERGE platform to identify novel disease targets, in exchange…
08 Sep 23
The US-based biotechnology company will receive an upfront payment from Otsuka and is eligible to receive additional development,…
08 Sep 23
The primary objectives of the collaboration include the identification of novel biomarkers and the enhancement of clinical trial…
07 Sep 23
The new research alliance will help advance three programmes over the next three years, of which two programmes…
06 Sep 23
BMS will obtain exclusive rights to develop and commercialise obexelimab, a bifunctional, non-cytolytic, humanised monoclonal antibody, in territories…
31 Aug 23
The agreement, which excludes geographical Europe, replaces the collaboration and license pact signed between both parties in 2021
30 Aug 23
Celularity to provide research support for Regeneron’s targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy
30 Aug 23
This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021
28 Aug 23
ST to partner with Dutch biotech company Treeway BV
24 Aug 23
Under the terms of the agreement, Aardvark Therapeutics will have the global development and commercialisation rights to ADAIR…